X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Rivaroxaban, usually known as Xarelto, is one of the most frequently prescribed blood thinners in Germany and the first approved factor Xa inhibitor. About 2 million people in Germany live with atrial fibrillation (a German figure, broadly comparable across Western countries), many of them on long-term anticoagulation. Unlike apixaban, rivaroxaban is taken only once a day — but the 15 and 20 mg tablets must mandatorily be combined with a meal, otherwise the absorption drops to 66%.
See more detail.gif)
Always take rivaroxaban 15/20 mg with a meal. Never stop it on your own — not even before operations or in the event of bleeding. Carry an anticoagulant card. In the event of brain-haemorrhage warning signs or a fall with a blow to the head, call the emergency services immediately (112; or 999/112 in the UK). Last updated: May 2026.
Rivaroxaban is the first approved direct oral anticoagulant (DOAC) from the group of factor Xa inhibitors. Below are the key facts for quick orientation; the individual points are explained in detail in the following chapters.
| Property | Details |
|---|---|
| Active substance | Rivaroxaban — direct oral anticoagulant (DOAC), factor Xa inhibitor |
| Trade name | Xarelto (originator product); rivaroxaban generics |
| ATC code | B01AF01 — direct factor Xa inhibitors |
| Mechanism of action | Direct, reversible inhibition of clotting factor Xa — interrupts the coagulation cascade |
| Main indications | Stroke prevention in atrial fibrillation, thrombosis/pulmonary embolism, thromboprophylaxis after joint replacement, CHD/PAD with ASA |
| Usual dose | 20 mg once daily (with food!); acute phase of thrombosis 15 mg twice daily; joint replacement 10 mg; vascular dose 2.5 mg twice daily |
| Intake | 15/20 mg must be taken with a meal! 2.5/10 mg independent of food |
| Onset of action | 2–4 hours |
| Half-life | 5–13 hours |
| Metabolism | CYP3A4 + P-glycoprotein; 35% renal excretion |
| Antidote | Andexanet alfa (Ondexxya); reserve: PPSB |
| Prescription status | Yes |
Rivaroxaban — known under the trade name Xarelto — is a direct oral anticoagulant (DOAC) from the group of factor Xa inhibitors. In 2008 it was the first approved factor Xa inhibitor and is to this day one of the most frequently prescribed blood thinners in Germany. Rivaroxaban prevents the formation of dangerous blood clots and thereby protects against strokes, thromboses and pulmonary embolisms.
Like all DOACs, rivaroxaban has important advantages over classic Marcumar (phenprocoumon): a fixed dose without regular coagulation checks, a fast onset of action and fewer interactions with foods. The most important distinguishing feature of rivaroxaban compared with its sister substance apixaban is the once-daily intake in most indications — an advantage for treatment adherence. In return, rivaroxaban in higher doses must be taken with a meal, which apixaban does not require.
Important to understand: rivaroxaban does not "thin" the blood in the literal sense either — it inhibits blood clotting so that no dangerous clots form. This is always a balancing act between protection from thromboses/strokes and an increased bleeding risk. Understanding and correctly managing this balancing act is the key to safe therapy.
Rivaroxaban directly and reversibly inhibits clotting factor Xa — a central hub of blood coagulation. Factor Xa catalyses the conversion of prothrombin to thrombin, which in turn converts fibrinogen into fibrin — the "glue" of a blood clot. By inhibiting factor Xa, the coagulation cascade is interrupted at a key point.
In contrast to heparin (which inhibits factor Xa only indirectly via antithrombin), rivaroxaban acts directly on factor Xa. And in contrast to Marcumar, which inhibits the formation of several clotting factors over days, rivaroxaban acts in a targeted and rapid manner — the onset of action occurs within 2 to 4 hours.
Rivaroxaban has a high bioavailability — but it is dose-dependent: the 10 mg tablet is well absorbed independently of food, whereas the 15 mg and 20 mg tablets only when taken with a meal (otherwise absorption falls to only 66 percent — hence the important intake rule). The half-life is 5 to 13 hours. Excretion occurs at about 35 percent via the kidneys (more than with apixaban), the rest via the liver and bowel. Rivaroxaban is metabolised via CYP3A4 and P-glycoprotein (P-gp) — these give rise to the most important interactions.
The most common indication. In non-valvular atrial fibrillation, the irregular heart rhythm readily causes clots to form in the atrium, which can trigger a stroke. Rivaroxaban lowers this risk significantly — in the pivotal ROCKET-AF study it was equivalent to Marcumar with a better brain-haemorrhage profile. Standard dose 20 mg once daily (15 mg with impaired kidney function).
In acute deep vein thrombosis of the leg or pulmonary embolism, rivaroxaban is used for acute treatment and secondary prevention — orally from the outset, without overlapping heparin. Regimen: 15 mg twice daily for 3 weeks, then 20 mg once daily.
After completed acute treatment, extended maintenance therapy with a reduced dose (10 mg once daily) can lower the recurrence risk — in those with a low bleeding risk.
After hip or knee replacement, rivaroxaban 10 mg once daily is used for thromboprophylaxis — 2 weeks after knee surgery, 5 weeks after hip surgery.
A special feature of rivaroxaban: at a low dose (2.5 mg twice daily) combined with ASA it is approved for risk reduction in stable coronary heart disease and peripheral arterial disease — the so-called "vascular dose" following the COMPASS study. Apixaban does not have this indication.
The dosing of rivaroxaban varies more by indication than with apixaban. Particularly important is the intake-with-food rule at higher doses:
| Indication | Dosage | With food? |
|---|---|---|
| Atrial fibrillation | 20 mg once daily | Yes — mandatory |
| Atrial fibrillation with renal impairment (eGFR 15–49) | 15 mg once daily | Yes — mandatory |
| Acute thrombosis/pulmonary embolism | 15 mg twice daily for 3 weeks | Yes — mandatory |
| Continuation: after 3 weeks | 20 mg once daily | Yes — mandatory |
| Extended prophylaxis after 6 months | 10 mg or 20 mg once daily | 10 mg independent; 20 mg with food |
| Thromboprophylaxis after joint replacement | 10 mg once daily | Independent |
| Vascular dose (CHD/PAD with ASA) | 2.5 mg twice daily | Independent |
| eGFR under 15 / dialysis | Not recommended | - |
This is the most important and most frequently misunderstood intake rule for rivaroxaban. The 15 mg and 20 mg tablets are only fully absorbed when taken with a meal — without food the bioavailability falls to about 66 percent, which jeopardises the clotting protection. The smaller doses (2.5 mg and 10 mg), by contrast, are independent of food.
The two most frequently prescribed factor Xa inhibitors in direct comparison — one of the most common questions, precisely because both work so similarly:
| Aspect | Rivaroxaban | Apixaban |
|---|---|---|
| Intake frequency | Once daily (advantage for compliance) | Twice daily |
| Intake with food | 15/20 mg mandatory | Independent of food |
| Renal excretion | 35% | 27% (advantage with renal impairment) |
| Gastrointestinal bleeding | Somewhat more frequent | Tends to be less |
| Brain-haemorrhage profile | Good (better than Marcumar) | Good |
| Vascular dose (CHD/PAD) | Yes (2.5 mg + ASA) | No |
| Antidote | Andexanet alfa | Andexanet alfa |
| Half-life | 5–13 hours | ~12 hours |
Clinical rule of thumb: In patients who value once-daily intake (better compliance), rivaroxaban is often favourable. With impaired kidney function, older age or an increased gastrointestinal bleeding risk, apixaban is frequently preferred. Both are excellent substances — the choice is made by the doctor individually according to kidney function, compliance and comorbidities.
Relevant for many patients being switched from Marcumar (phenprocoumon):
Clinical rule of thumb: For most patients with atrial fibrillation or thrombosis, DOACs such as rivaroxaban are today the first-line option. Marcumar remains indispensable with mechanical heart valves, the most severe renal insufficiency and certain other constellations.
The most important safety topic. Rivaroxaban increases — like all anticoagulants — the bleeding risk. A distinction is made between:
Risk factors for bleeding: older age, impaired kidney function, previous bleeding, stomach ulcers, concurrent intake of NSAIDs, ASA or other blood thinners, uncontrolled high blood pressure, alcohol abuse. The HAS-BLED score helps with risk assessment — but it leads to optimisation of the risk factors, not to forgoing anticoagulation.
Because rivaroxaban is taken once daily in most indications, different rules apply than for substances dosed twice daily:
Before planned operations or invasive procedures, rivaroxaban must as a rule be temporarily paused. As with all DOACs, no "bridging" with heparin is usually necessary, because the substance acts quickly and is broken down again quickly:
Important: Pausing before procedures must always be doctor-directed — never on your own. Before every planned procedure (including at the dentist!), the anticoagulation should be discussed with the treating doctor.
